Literature DB >> 15315165

TLR2 mRNA upregulation in ischemic lobes in mouse partial hepatic ischemia/reperfusion injury model.

Jinxiang Zhang1, Heshui Wu, Lin Wang, Jinhui Zhang, Hui Wang, Qichang Zheng.   

Abstract

To investigate TLR2 (Toll-like receptor 2) mRNA expression in ischemic hepatic lobes under the condition of partial hepatic ischemia/reperfusion injury in BALB/c mice and its relationship with liver function impairment. A partial ischemia/reperfusion injury model was established. The portal vein and hepatic artery supply to the median and left lobes of the liver were obstructed by an atraumatic artery micro-clip, with the obstruction lasting for about 60 min. Then reperfusion was fulfilled by removal of the clip. The liver samples were collected at the 4th h after the restoration of blood inflow. Total RNA was extracted from the liver samples and analyzed quantitatively by method of real-time PCR. At the same time, portal vein serum and plasma were taken respectively for further detection of the level of endotoxin, tumor necrosis factor alpha (TNF-alpha) and plasmic alanine aminotransferase (pALT). The results indicated that TLR2 mRNA in ischemic lobe was up-regulated markedly in mice partial liver ischemia/reperfusion injury model compared to that in sham operation group (deltaCt: 1.05 +/- 1.02 vs 5.08 +/- 1.36, P<0.001). The level of portal vein pALT and TNF-alpha increased significantly (112.32 +/- 17.56 pg/ml vs 6.07 +/- 5.33 pg/ml, P<0.01; 890 +/- 127 microm/L vs 30 +/- 5 microm/L, P<0.001) . However, the level of portal vein endotoxin remained below the normal line, suggesting a state of non-endotoxemia. TLR2 mRNA expression in ischemic lobe, as well as portal vein pALT and TNF-alpha, was up-regulated in the model of mice partial ischemia/reperfusion injury, suggesting the involvement of TLR2 in ischemia/reperfusion pathological process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315165     DOI: 10.1007/bf02885414

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

Authors:  Geoffrey B Johnson; Gregory J Brunn; Yuzo Kodaira; Jeffrey L Platt
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

2.  Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors.

Authors:  E Cario; I M Rosenberg; S L Brandwein; P L Beck; H C Reinecker; D K Podolsky
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes.

Authors:  T Matsumura; A Ito; T Takii; H Hayashi; K Onozaki
Journal:  J Interferon Cytokine Res       Date:  2000-10       Impact factor: 2.607

4.  Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages.

Authors:  T Matsuguchi; T Musikacharoen; T Ogawa; Y Yoshikai
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

5.  Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat.

Authors:  L M Colletti; D G Remick; G D Burtch; S L Kunkel; R M Strieter; D A Campbell
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes.

Authors:  S Frantz; R A Kelly; T Bourcier
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

Review 7.  Hepatic ischemia/reperfusion injury--a fresh look.

Authors:  Constantino Fondevila; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Exp Mol Pathol       Date:  2003-04       Impact factor: 3.362

8.  Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia.

Authors:  Yoshimitsu Kojima; Shohachi Suzuki; Yasuo Tsuchiya; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  Transpl Int       Date:  2003-02-27       Impact factor: 3.782

9.  [TLR4 is involved in hepatic ischemia/reperfusion injury in mice].

Authors:  He-shui Wu; Lin Wang; Ori Rotstein
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-07

10.  Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling.

Authors:  R B Yang; M R Mark; A Gray; A Huang; M H Xie; M Zhang; A Goddard; W I Wood; A L Gurney; P J Godowski
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

View more
  6 in total

1.  Regulation of TLR2 and NLRP3 in primary murine renal tubular epithelial cells.

Authors:  Sashi G Kasimsetty; Sean E DeWolf; Alana A Shigeoka; Dianne B McKay
Journal:  Nephron Clin Pract       Date:  2014-09-24

2.  Effect of Salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive tract congestion.

Authors:  Zhi-Yong Zhang; Xiao-Ping Chen; Qi-Ping Lu
Journal:  Front Med China       Date:  2010-05-10

3.  Protection against hepatic ischemia/reperfusion injury via downregulation of toll-like receptor 2 expression by inhibition of Kupffer cell function.

Authors:  Jin-Xiang Zhang; He-Shui Wu; Hui Wang; Jin-Hui Zhang; Yang Wang; Qi-Chang Zheng
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

Review 4.  TLR2 and TLR4 in ischemia reperfusion injury.

Authors:  F Arslan; B Keogh; P McGuirk; A E Parker
Journal:  Mediators Inflamm       Date:  2010-06-09       Impact factor: 4.711

5.  The immunomodulatory role of carbon monoxide during transplantation.

Authors:  Mariane Tami Amano; Niels Olsen Saraiva Camara
Journal:  Med Gas Res       Date:  2013-01-07

6.  Toll-like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia.

Authors:  Hemanshu Patel; Sidney G Shaw; Xu Shi-Wen; David Abraham; Daryll M Baker; Janice C S Tsui
Journal:  Cardiol Res Pract       Date:  2012-02-07       Impact factor: 1.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.